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The emergence and dissemination of multi-drug resistant pathogens is a global concern.
Moreover, even greater levels of resistance are conferred on bacteria when in the form of
biofilms (i.e., complex, sessile communities of bacteria embedded in an organic polymer
matrix). For decades, antimicrobial peptides have been hailed as a potential solution to
the paucity of novel antibiotics, either as natural inhibitors that can be used alone or
in formulations with synergistically acting antibiotics. Here, we evaluate the potential
of the antimicrobial peptide nisin to increase the efficacy of the antibiotics polymyxin
and colistin, with a particular focus on their application to prevent biofilm formation of
Pseudomonas aeruginosa. The results reveal that the concentrations of polymyxins that
are required to effectively inhibit biofilm formation can be dramatically reduced when
combined with nisin, thereby enhancing efficacy, and ultimately, restoring sensitivity.
Such combination therapy may yield added benefits by virtue of reducing polymyxin
toxicity through the administration of significantly lower levels of polymyxin antibiotics.
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INTRODUCTION
The increasing spread of antibiotic resistance in Gram-negative bacteria, particularly in
Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae, represents a major
global medical challenge (Bergen et al., 2012). Mortality, morbidity, and health care costs are
substantially increased as a result of infections caused by these pathogens (Boucher et al., 2009).
The situation is exacerbated by the lack of progress with respect to the clinical development
of new antibiotics for Gram-negative bacteria over the last few decades (Carlet et al., 2012).
These factors have led to a revival in the use of polymyxins to treat recalcitrant infections that
are resistant to most or all other currently available antibiotics. In clinical settings, colistin (i.e.,
polymyxin E) and polymyxin B were initially used to treat numerous infections caused by Gram-
negative bacteria, including sepsis, wound infections, urinary tract infection, pneumonia, and
catheter-based infections (Landman et al., 2008). Polymyxins exert their antimicrobial action via
direct interaction with the lipid A component of the lipopolysaccharide (LPS), resulting in the
increased permeability of the bacterial cell membrane (Velkov et al., 2010). Although introduced
in the 1950s, colistin and polymyxin B were abandoned in the 1970s due to reports of serious
toxic effects, mainly to the kidney and nervous system (Velkov et al., 2013). However, the rapid
increase in resistance to all other antibiotics necessitated their re-evaluation and in the 1980s
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colistin was reintroduced to control infection or colonization
by P. aeruginosa in patients with cystic fibrosis (CF) (Nation
and Li, 2009). Despite their relatively recent reintegration in
clinical practice, microbial resistance is already an issue of
significance, with reports of the existence of plasmid-borne
polymyxin resistance determinants (Liu et al., 2016) potentiating
the rapid spread of resistance to these last-line antibiotics.
Furthermore, antibiotic therapy by these, and other antibiotics,
is hindered by the innate antibiotic resistance of bacteria
present in biofilms (complex, sessile communities of bacteria
embedded in an organic polymer matrix), making novel anti-
biofilm strategies highly desirable (Marcinkiewicz et al., 2013).
Approaches to overcome these issues, including drug discovery
programs for the development of new polymyxin derivatives
that are safer and more efficacious, have met with little success
(Velkov et al., 2016). An alternative option is the use of
polymyxins in combination with other antimicrobial agents
including peptide inhibitors. Indeed, such strategies for peptide-
antibiotic combinations to address issues related to prevent
and eradicate bacterial biofilms formed by multidrug-resistant
bacteria show great promise (Reffuveille et al., 2014; de la
Fuente-Núñez and Hancock, 2015). In keeping with this line
of enquiry, there has been a particular focus on assessing
and enhancing the benefits of applying lantibiotics in clinical
settings (Cotter et al., 2013; Field et al., 2015a). Lantibiotics
are ribosomally synthesized peptides that are distinguished by
the presence of unusual amino acids including lanthionine
and/or methyllanthionine (Breukink and de Kruijff, 1999;
Bierbaum and Sahl, 2009), and have become the focus of
much biomedical and pharmaceutical research due to their high
potency in vitro, numerous modes of action and capacity to
destroy target cells rapidly (Cotter et al., 2005; Cavera et al.,
2015). The most thoroughly investigated lantibiotic is nisin,
a 34 amino acid polycyclic peptide that exhibits antibacterial
activity against a wide range of clinical and food-borne pathogens
that is widely used as a natural biopreservative (Delves-
Broughton et al., 1996; Deegan et al., 2006). It has frequently
been suggested that the efficacy of nisin could be further
improved through combination with other antimicrobials or
membrane-active substances (Cavera et al., 2015; Field et al.,
2015b). Indeed, several studies have demonstrated synergistic
relationships between conventional antibiotics and nisin. The
majority of these studies have involved Gram-positive bacteria
such as staphylococci, including methicillin-resistant forms
(Piper et al., 2009; Dosler and Gerceker, 2011; Okuda et al.,
2013), enterococci (Tong et al., 2014), including vancomycin-
resistant enterococci (Brumfitt et al., 2002), and streptococci
(Lebel et al., 2013). Nisin-antibiotic combinations have also been
shown to be effective against Gram-positive bacterial biofilms
(Okuda et al., 2013; Field et al., 2015c). Recent combinatorial
nisin-antibiotic investigations have been directed against Gram-
negative bacteria. For example, nisin displayed synergistic activity
with the antibiotics penicillin, streptomycin, chloramphenicol
and rifampicin against P. fluorescens (Naghmouchi et al., 2012),
and with colistin against Salmonella choleraesuis, P. aeruginosa,
Yersinia enterocolitica, and Escherichia coli (Naghmouchi et al.,
2013). Similarly, nisin-ceftriaxone and nisin-cefotaxime were
found to be highly synergistic when applied against clinical
isolates of S. enterica serovar Typhimurium, as evident by
checkerboard and time-kill assays (Rishi et al., 2014). While
synergistic in vitro activities of antibiotics and antimicrobial
cationic peptides in combination against biofilms of P. aeruginosa
have been demonstrated (Dosler and Karaaslan, 2014), the effects
of the prototypical lantibiotic nisin and antibiotic combinations
on biofilm formation of Gram-negative bacteria has not been
investigated. Here we assess the impact of combining nisin
with a variety of clinical antibiotics and establish that nisin
exhibits enhanced inhibitory activity in combination with either
polymyxin B or colistin. Furthermore, we reveal that the
combinations are more effective at inhibiting P. aeruginosa
biofilm formation compared to when either antimicrobial is
used alone. Importantly, the results provide data on effective
synergistic concentrations that may allow for the effective clinical
use of significantly lower levels of the nephrotoxic antibiotics
colistin and polymyxin B
MATERIALS AND METHODS
Bacterial Strains and Growth Conditions
Lactococcus lactis NZ9700 was grown in M17 broth
supplemented with 0.5% glucose (GM17) or GM17 agar at
30◦C. E. coli, K. pneumoniae and Pseudomonas strains were
grown in Luria–Bertani (LB) broth [5 g L−1 yeast extract
(Oxoid), 10 g L−1 tryptone (Oxoid) and 10 g L−1 NaCl (Merck)],
incubated overnight at 37◦C and shaken at 170 rpm.
Minimum Inhibitory Concentration
Assays
Minimum inhibitory concentration (MIC) determinations were
carried out in triplicate in 96 well microtiter plates as described
previously (Field et al., 2010, 2012). Briefly, target strains were
grown overnight in the appropriate conditions and medium,
subcultured into fresh broth and allowed to grow to an OD600
of ∼0.5, diluted to a final concentration of 105 cfu ml−1 in a
volume of 0.2 ml. Chloramphenicol, penicillin G, erythromycin,
colistin, and polymyxin B (Sigma) were resuspended in LB media
to a stock concentration of 128 or 256 µg/ml. The antibiotics
were adjusted to 16, 32, 64, or 128 µg/ml starting concentration
and twofold serial dilutions of each compound were made in
96 well plates for a total of 12 dilutions. Purified nisin was
adjusted to a 100 µM (when using E. coli, K. pneumoniae, and
Pseudomonas putida as a target) or 200 µM (P. aeruginosa)
starting concentration and twofold serial dilutions of each
peptide were carried out. The target strain was then added and
after incubation for 16 h at 37◦C and the MIC was read as the
lowest peptide concentration causing inhibition of visible growth.
Nisin Purification
Nisin was purified according to previously described protocols
(Field et al., 2010; Healy et al., 2013). The purified nisin peptide
was subjected to MALDI-ToF Mass Spectrometric analysis to
confirm purity before use.
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Growth Curve Experiments
For growth experiments, overnight cultures were transferred
(107 cfu ml−1 in a volume of 1.0 ml.) into LB supplemented
with the relevant concentration of nisin A and antibiotic/peptide
combinations, and subsequently 0.2 ml was transferred to 96
well microtiter plates (Sarstedt). Cell growth was measured
spectrophotometrically over 24 or 48-h periods by using
a SpectraMax M3 spectrophotometer (Molecular Devices,
Sunnyvale, CA, USA).
Biofilm Formation
Static microtiter plate assays based on a previous study (Kelly
et al., 2012), but with modifications to optimize the assay. Briefly,
a 1:100 dilution was performed by adding 2 µl of log phase cells
(107 CFU ml−1 of each culture) to 198 µl of LB in wells of a
sterile 96-well microtiter plate (Sarstedt, Leicester, UK), giving
a starting inoculum of 105 CFU ml−1; 200 µl of LB was added
to a set of wells as a negative control. All wells were seeded
in triplicate. Microtiter plates were then incubated at 37◦C for
24 h to allow biofilm formation to occur and Washing (PBS)
and staining of wells (0.05% crystal violet) was carried out as
described previously (Field et al., 2015c).
Inhibition of Biofilm Formation
Antibiotics (colistin or polymyxin) were added to the microtiter
plate wells at 1/2×, 1/5×, 1/10×, and nisin peptide at 1/3× or
1/10× and combinations thereof the relevant MIC as previously
determined. Log phase cells were added to give a starting
inoculum of 105 CFU ml−1; all wells were seeded in triplicate.
The plate was incubated for 24 h, at 37◦C and cell growth
measured using a SpectraMax M3 spectrophotometer (Molecular
Devices, Sunnyvale, CA, USA). The plates were removed and
washing (PBS) and staining of wells (0.05% crystal violet)
was carried out as described previously (Field et al., 2015c).
Absorbance was measured at 595 nm using a microtiter plate
reader (Molecular Devices Spectramax M3, Sunnyvale, CA,
USA). Data obtained in triplicate were calculated and expressed
as the mean± standard deviations.
RESULTS
Bacterial Susceptibility to Antimicrobial
Compounds
Minimum inhibitory concentration with purified nisin A
peptide, as well as a range of antibiotics including penicillin,
erythromycin, chloramphenicol, colistin, and polymyxin B, were
carried out to establish suitable concentrations for combinatorial
studies with nisin against the Gram-negative targets E. coli K12
MG1655, K. pneumoniae NCIMB 13218, P. putida CA-3, and
P. aeruginosa PA-01. Activity against the target strains required
a relatively high concentration of nisin (50–200 µg/ml). These
values were in agreement with data obtained by Naghmouchi
et al. (2013) against a panel of Gram-negative strains and,
yet again, highlights the relative resistance of Gram-negative
bacteria to nisin compared to Gram-positive strains, with
some examples of the latter having MICs in the nanomolar
(nM) range. E. coli, Klebsiella and Pseudomonas strains were
relatively resistant to erythromycin and penicillin but, with the
exception of K. pneumoniae NCIMB 13218, were sensitive to
chloramphenicol. MICs for colistin and polymyxin B against
E. coli K12 MG1655 were in close agreement with previously
established figures against strains of E. coli (Corvec et al., 2013).
Similarly, colistin and polymyxin B exhibited almost identical
activity (Gales et al., 2011) against K. pneumoniae NCIMB
13218 and the Pseudomonas strains and were within previously
established ranges (MIC90, 2 µg/ml) (Gales et al., 2001).
Growth Curve-Based Comparisons of
the Activity of Nisin A and Antibiotic
Combinations
Having established the MIC values for nisin A and a range
of antibiotics against the representative Gram-negative strains,
growth curves were performed in order to reveal the impact of
sub-lethal concentrations of nisin A and antibiotics (alone and
in combination) on bacterial growth. The final concentration
of nisin or antibiotic used for each organism was a fraction of
the previously determined MIC value (i.e., 1/2×, 1/3×, 1/4×,
etc.) and combinations thereof. It was decided that penicillin and
chloramphenicol should be included for combinatorial analysis
given previous reports of synergism between these antibiotics
and nisin A against strains of Pseudomonas (Naghmouchi
et al., 2013). When nisin + penicillin, nisin + erythromycin
or nisin + chloramphenicol combinations were employed
against E. coli K12 MG1655, K. pneumoniae NCIMB 13218,
P. putida CA-3, and P. aeruginosa PA-01, little to no synergistic
effects were observed at the sub-inhibitory concentrations used
(data not shown). However, pronounced inhibitory effects were
observed when colistin or polymyxin B was combined with
nisin, compared to the untreated control or when each of
the antimicrobials was used alone (Figure 1). In the case of
E. coli K12 MG1655, a combination of 1/8× MIC (0.05 µg/ml)
colistin or polymyxin and 1/5× MIC (10 µg/ml) nisin A
resulted in complete inhibition of growth (Figures 1A,B).
Similarly, no growth of K. pneumoniae was observed when
1/2× MIC (0.75 µg/ml) of either colistin or polymyxin was
used in combination with 1/3× MIC (16.66 µg/ml) nisin A
(Figures 1C,D). Nisin at 1/3× MIC (16.66 µg/ml) had little
impact of the growth of P. putida CA-3 when compared to the
untreated control (Figure 1F), but no growth was observed over
the 36 h period when combined with colistin or polymyxin at
1/4×MIC (0.1 µg/ml and 0.2 µg/ml, respectively). Finally, in the
case of P. aeruginosa PA-01, polymyxin and colistin at 1/2×MIC
in combination with 1/3×MIC nisin was sufficient to completely
inhibit growth (Figures 1G,H).
Inhibition of Biofilm Formation with
Purified Nisin A and Antibiotic
Combinations
Prior to carrying out combinatorial experiments against biofilms,
the biofilm-forming capabilities of the target strains was assessed
and all demonstrated the ability to form biofilms as determined
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FIGURE 1 | Growth curve analysis of (A) E. coli MG1655 in the
presence of 1/5× minimum inhibitory concentration (MIC; 10 µg/ml)
nisin A (green triangle), 1/8× MIC (0.05 µg/ml) colistin (blue circle), in
combination (red diamond) and untreated control (black circle) (B)
1/5× MIC (10 µg/ml) nisin A (green triangle), 1/8× MIC (0.05 µg/ml)
polymyxin B (blue circle) in combination (red diamond), (C) Klebsiella
pneumoniae NCIMB 13218 in the presence of 1/3× MIC (16.66 µg/ml)
nisin A (green triangle), 1/2× MIC (0.75 µg/ml) colistin (blue circle), in
combination (red diamond) and untreated control (black circle), (D)
1/3× MIC (16.66 µg/ml) nisin A (green triangle), 1/2× MIC (0.75 µg/ml)
polymyxin (blue circle), in combination (red diamond) and untreated
control (black circle), (E) Pseudomonas putida CA-3 in the presence of
1/3× MIC (16.66 µg/ml) nisin A (green triangle), 1/4× MIC (0.1 µg/ml)
colistin (blue circle), in combination (red diamond) and untreated
control (black circle), (F) 1/3× MIC (16.66 µg/ml) nisin A (green
triangle), 1/4× MIC (0.2 µg/ml) polymyxin B (blue circle), in
combination (red diamond) and untreated control (black circle), and
(G) P. aeruginosa PA-01 in the presence of 1/4× MIC (50 µg/ml) nisin A
(green triangle), 1/2× MIC (0.75 µg/ml) colistin (blue circle), in
combination (red diamond) and untreated control (black circle), (H)
1/4× MIC (50 µg/ml) nisin A (green triangle), 1/2× MIC (0.75 µg/ml)
polymyxin B (blue circle), in combination (red diamond) and untreated
control (black circle).
using 96 well flat-bottomed polystyrene plates and staining
with crystal violet (data not shown). We employed the same
methodology to study the ability of nisin A and colistin or
polymyxin combinations to inhibit biofilm formation using
P. aeruginosa PA-01 as a representative strain. P. aeruginosa was
selected as a target due to its ability to form biofilms in various
environments, its natural resistance to many currently utilized
antibiotics and its association with several chronic infectious
diseases (Hall-Stoodley et al., 2004). For biofilm prevention
studies, colistin, or polymyxin was employed at concentrations
1/2×, 1/5×, or 1/10× MIC (0.78, 0.31, and 0.15 µg/ml,
respectively) while nisin was used at 1/4× or 1/10× MIC (50
and 5 µg/ml), as well as combinations thereof. Growth was
monitored spectrophotometrically (as Absorbance OD600) over
24-h, followed by staining and optical density readings at 595 nm
(OD595). Notably, none of the antimicrobials inhibited biofilm
formation when used alone (Figures 2B,D). Indeed, although
colistin and polymyxin, when utilized at 1/2× MIC, exerted a
significant delay in growth (as evident by the extended lag phase)
compared to the untreated control (Figures 2A,C), only colistin
caused a small reduction in biofilm mass (Figure 2D). When
lower concentrations (1/10×) of the antibiotics were used, even
in combination with nisin, a similar biofilm density was observed
to that of the untreated control. However, it was established
that combinations of nisin at 1/4× MIC in combination with
1/2× or as little as 1/5× MIC polymyxin B or colistin were
able to completely inhibit biofilm formation (∗∗∗p < 0.001)
of P. aeruginosa PA-01 due to the inhibition of growth of the
bacteria (Figures 2B,D). Finally, no significant difference in
biofilm density was apparent compared to the untreated control
for all other combination of nisin and colistin or polymyxin B.
DISCUSSION
Infections caused by multi-drug resistant bacteria constitute the
leading cause of serious healthcare-associated infections and are
responsible for extended periods of hospital stay, severe illness,
mortality, and increased economic burden. The polymyxins
now play a critical role in the antibiotic arsenal, as they are
one of few, and occasionally the sole, antimicrobial agent
maintaining efficacy against multi-drug resistant Gram-negative
pathogens that frequently cause life threatening infections in
the most vulnerable of patient populations. Critically, there are
clinical reports confirming that Gram-negative bacteria have
developed resistance even to polymyxins (Falagas et al., 2008;
Di Pilato et al., 2016), underpinning the necessity for strategies
to reduce the effective dose needed for these antibiotics to help
prevent or delay the further spread of resistance. The ability
of these organisms to form biofilms must also be taken into
consideration given the impermeable nature of many biofilms
further contributes to resistance. Biofilm suppression can be
achieved in three ways, namely: (i) inhibition of the initial
planktonic population, (ii) prevention of the initial adhesion
of cells to the surface, and (iii) removal of the established
biofilm. Because biofilm-associated bacteria are not affected by
therapeutically relevant concentrations of antimicrobial agents,
anti-biofilm therapies have generally focused on the inhibition
of biofilm formation (Dosler and Karaaslan, 2014). Here, we
set out to examine, for the first time, the ability of nisin,
when used in conjunction with a selection of conventional
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FIGURE 2 | Growth curve analysis of P. aeruginosa PA-01 (A) in the presence of nisin (1/4×, 1/10× MIC) and polymyxin B (1/2×, 1/5×, 1/10× MIC) and
combinations thereof as carried out in 96 well microtiter plates, followed by crystal violet (CV) staining for the detection of biofilm formation (B) and
P. aeruginosa PA-01 (C) in the presence of nisin (1/4×, 1/10× MIC) and colistin (1/2×, 1/5×, 1/10× MIC) and combinations thereof, followed by CV
staining (D). The means and standard deviations of triplicate determinations are presented. Asterisks indicate statistically significant differences (Student’s t-test)
between peptide and antibiotic combinations used at similar concentration (∗∗∗p < 0.001).
antibiotics, to control a range of Gram-negative bacteria with the
ultimate aim of identifying superior anti-biofilm combinations.
Indeed, following MIC determinations and growth curve analysis
in the presence of nisin and selected antibiotic combinations,
substantial enhanced inhibitory relationships were only observed
for nisin in combination with colistin or polymyxin B.
The results reveal that sub-inhibitory levels (1/5× MIC and
1/4× MIC for colistin and nisin, respectively) can effectively
prevent biofilm formation through total inhibition of growth.
Notably, nisin alone had no effect on growth at any of the
concentrations utilized. The poor activity of nisin and other
lantibiotics toward Gram-negative bacteria is ascribed to the
outer membrane (OM) of the Gram-negative cell wall which
acts as a physical barrier, impeding the access of the peptides
to the cytoplasmic membrane (Nikaido and Vaara, 1985).
Indeed, previous studies have confirmed the enhanced efficacy
of bioengineered nisin derivatives against Gram-negative bacteria
in which the OM no longer functions as an impenetrable
barrier following treatment with Polymyxin B nonapeptide
(PMBN; Field et al., 2012). The potential benefits associated
with identifying antibiotics that function synergistically with
nisin are manifold. While antibiotic resistance has become a
major obstacle, significant resistance to nisin outside of the
laboratory has yet to be reported despite its widespread use as
a food preservative (Breukink and de Kruijff, 1999) and thus
the use of nisin-antibiotic combinations may prevent/overcome
the emergence of resistance. Indeed, such approaches appear
particularly promising for combinations of antimicrobials
that target different sites. Additionally, combination therapy
may permit the dose of the individual antimicrobials to be
reduced and consequently counteract the development of drug-
resistance in bacteria. Furthermore, the opportunity also exists
to combine nisin and colistin/polymyxin with other antibiofilm
agents including quorum sensing (QS) inhibitors such as
polyphenolic compounds (baicalin hydrate, epigallocatechin) or
enzymes for signal molecule destruction that affect biofilms
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via non-microbicidal mechanisms, but instead target specific
molecular pathways that regulate biofilm formation (Brackman
and Coenye, 2015). For example, Human HDP LL-37 and
the bovine neutrophil peptide indolicidin have previously been
shown to prevent P. aeruginosa PAO1 biofilm formation at sub-
inhibitory concentrations by downregulating the genes essential
for cell attachment and biofilm formation (Overhage et al.,
2008). Similarly, the antibiotics azithromycin and ceftazidime
demonstrated inhibitory effects against P. aeruginosa biofilm
through the downregulation of a range of QS-regulated virulence
factors and adhesion abilities (Skindersoe et al., 2008).
CONCLUSION AND PERSPECTIVES
The incidence of multi-drug resistant bacteria continues
unabated despite the best efforts of antimicrobial stewardship
and stringent infection control practices in hospitals. In addition
to the urgent demand for newer antibiotics, imaginative, and
judicious approaches are required to protect the efficacy of
the current last resort compounds. The data presented here
demonstrates the potential for nisin and conventional antibiotic
combinations to act as potent antimicrobial and anti-biofilm
agents against Gram-negative pathogens including P. aeruginosa.
The enhanced activities of combinations of nisin A with both
colistin and polymyxin B observed here for the first time
to prevent P. aeruginosa biofilm formation has significant
implications for their future use as novel therapeutics in the
treatment of multi-drug resistant bacteria. Furthermore, these
data reinforce the idea that bacteriocins can form a novel strategy
to prevent adhesion and to control biofilm formation by clinically
relevant pathogens and ultimately may facilitate the use of
lower concentrations of polymyxin antibiotics in situations where
the levels currently exercised are of concern from a toxicity
standpoint.
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